Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Cash-Strapped Catalyst Bio Forced Into Quick Sale
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
You may also be interested in...
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
The neoantigen immunotherapy company is a casualty of slow R&D progress and a squeeze on biotech finance – and more firms are in the firing line.
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.